Cellular contribution to left and right atrial dysfunction in chronic arterial hypertension in pigs

Ge Jin¹,², Martin Manning¹, Gabriel Adelsmayr³, Michael Schwarzl¹, Alessio Alogna⁴,⁵, Patrick Schönleitner¹, David Zweiker¹, Florian Blaschke⁴,⁵, Mohammad Sherif¹, Snjezana Radulovic¹, Paulina Wakula³,⁵, Sylvia Schauer⁶, Gerald Höfler⁶, Ursula Reiter³, Gert Reiter⁷, Heiner Post⁴,⁵, Daniel Scherr¹, Karoly Acsai⁸, Gudrun Antoons⁹, Burkert Pieske⁴,⁵,¹⁰ and Frank R. Heinzel⁴,⁵,¹,‡

¹Division of Cardiology, Medical University of Graz, Graz, Austria; ²Department of Radiology, Medical University of Graz, Graz, Austria; ³Department of Internal Medicine and Cardiology, Charité—Universitätsmedizin Berlin, Campus Virchow-Klinikum, Augustenburgerplatz 1, Berlin, 13353, Germany; ⁴DKH (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany; ⁵Department of Pathology, Medical University of Graz, Graz, Austria; ⁶Research & Development, Siemens AG Healthcare, Vienna, Austria; ⁷Division of Pharmacology and Pharmacotherapy, University of Szeged, Szeged, Hungary; ⁸Faculty of Sciences, Department of Organic and Macromolecular Chemistry, Ghent University, Ghent, Belgium; and ¹⁰Department of Cardiology, German Heart Center Berlin (DZHK), Berlin, Germany

Abstract

Aims Atrial contractile dysfunction contributes to worse prognosis in hypertensive heart disease (HHD), but the role of cardiomyocyte dysfunction in atrial remodelling in HHD is not well understood. We investigated and compared cellular mechanisms of left (LA) and right atrial (RA) contractile dysfunction in pigs with HHD.

Methods and results In vivo electrophysiological and magnetic resonance imaging studies were performed in control and pigs treated with 11-deoxycorticosterone acetate (DOCA)/high-salt/glucose diet (12 weeks) to induce HHD. HHD leads to significant atrial remodelling and loss of contractile function in LA and a similar trend in RA (magnetic resonance imaging). Atrial remodelling was associated with a higher inducibility of atrial fibrillation but unrelated to changes in atrial refractory period or fibrosis (histology). Reduced atrial function in DOCA pigs was related to reduced contraction amplitude of isolated LA (already at baseline) and RA myocytes (at higher frequencies) due to reduced intracellular Ca release (Fura 2-AM, field stimulation). However, Ca regulation differed in LA and RA cardiomyocytes: LA cardiomyocytes showed reduced sarcoplasmic reticulum (SR) [Ca], whereas in RA, SR [Ca] was unchanged and SR Ca²⁺-ATPase activity was increased. Sodium–calcium exchanger (NCX) activity was not significantly altered. We used ORM-10103 (3 μM), a specific NCX inhibitor to improve Ca availability in LA and RA cardiomyocytes from DOCA pigs. Partial inhibition of NCX increased Ca²⁺ transient amplitude and SR Ca in LA, but not RA cells.

Conclusions In this large animal model of HHD, atrial remodelling in sinus rhythm in vivo was related to differential LA and RA cardiomyocyte dysfunction and Ca signalling. Selective acute inhibition of NCX improved Ca release in diseased LA cardiomyocytes, suggesting a potential therapeutic approach to improve atrial inotropy in HHD.

Keywords Atrial remodelling; Calcium; Cardiomyocytes; Contractility; Sodium–calcium exchanger

Introduction

The heart’s atria contribute to ventricular filling and cardiac output, determine heart rhythm, and participate in endocrine signalling. Atrial remodelling has been largely investigated as a substrate for atrial fibrillation (AF). However, the pivotal role of atrial dysfunction in the development of heart failure (HF) even in the absence of AF is increasingly recognized.

Indeed, atrial contractile dysfunction in HF is associated with reduced exercise capacitance and worse prognosis. Important clinical triggers of atrial remodelling are increased mechanical load and neurohumoral activation, as

© 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
seen in HF and also in early cardiac remodelling as a result of systemic arterial hypertension and increased left ventricular (LV) pressure. Indeed, left atrial (LA) enlargement is present in about one-third of hypertensive patients, and interestingly, the right atrium (RA) is also involved.

The pathophysiology of atrial remodelling is complex and likely aetiology specific but has been mainly studied in animal models of AF or chronic HF. AF is a clinically relevant manifestation of atrial remodelling, and also contributes to its progression. AF reduces the atrial effective refractory period (AERP), thus promoting AF sustainability (‘AF begets AF’). The effects of other clinical conditions such as arterial hypertension and ageing on atrial remodelling are less well understood. We have shown that in the presence of AF, the induction of arterial hypertension worsens atrial remodelling and arrhythmogeneity, however, without further shortening of AERP. Arterial hypertension also promotes atrial remodelling independent of AERP in aged rats.

While systemic arterial hypertension is sufficient to initiate maladaptive LA and RA remodelling, cellular mechanisms have not yet been investigated in a large animal model. Studies in rat suggest impairment of LA cardiomyocyte Ca\(^{2+}\) homeostasis. Pigs have a cardiac anatomy more close to humans. In the present study, we therefore characterized the functional and cellular adaptation of the LA and RA to moderate systemic arterial hypertension in pigs to test the hypothesis that atrial dysfunction in vivo is associated with contractile dysfunction of atrial cardiomyocytes. In addition, we explore an approach to improve cardiomyocyte Ca\(^{2+}\) signalling in hypertensive atrial remodelling using a novel inhibitor of sarcolemmal Na\(^+\)/Ca\(^{2+}\) exchanger (NCX).

**Methods**

Animal handling was in accordance with the Guide for the Care and Use of Laboratory Animals (National Institutes of Health, USA). Experimental protocols were approved by the local bioethics committee of Vienna, Austria (BMWF-66.010/0108-II/3b/2010, BMWF-66.010/0128-II/3b/2012, and BMWF-66.010/0091-II/3b/2013).

**Experimental model**

To induce arterial hypertension and hypertensive heart disease (HHD), 16 female landrace pigs (10–14 weeks of age) were treated with 11-deoxycorticosterone acetate (DOCA), combined with a high-sugar/salt/potassium diet (300 g sugar, 40 g salt, and 6 g potassium per day) for 12 weeks. DOCA pellets with a 90 day release (Innovative Research of America, USA) were implanted subcutaneously in the inguinal region under sedoanalgesia with ketamine (20 mg/kg body weight) and midazolam (0.25 mg/kg). Healthy pigs (n = 31) of comparable weight were used as control (CTRL, 70 ± 6 vs. 60 ± 9 kg at the time of the final experiment). Supporting Information, Figure S1 summarizes the use of animals for the experimental protocols.

**Final experiment**

A group of seven DOCA and eight CTRL pigs were sedated with ketamine and midazolam as stated earlier. Non-invasive blood pressure measurements were performed by tail cuff sphygmomanometry. Endotracheal intubation was performed after intravenous administration of propofol 1% (0.1 mL/kg). Narcosis was sustained with sevoflurane (1.5–2.5%), fentanyl (35 μg/kg/h), midazolam (1.2 mg/kg/h), ketamine (2–8 mg/kg/h), and pancuronium (0.2 mg/kg/h). A balanced crystalloid infusion was administered at a fixed rate of 10 mL/kg/h. After instrumentation, a bolus of heparin (100 IE/kg) was administered, followed by a continuous infusion of 100 IE/kg/h.

**In vivo electrophysiological studies**

Pigs were then instrumented with a quadripolar stimulation catheter (5F Boston Scientific) in the high RA and a decapolar catheter (6F Decapolar, Biosense Webster) in the coronary sinus. AERP was determined by an S1–S2 stimulation protocol (1 ms pulse at twice diastolic threshold at cycle lengths 400, 300, and 240 ms). Inducibility of AF was assessed by burst protocols (1 ms pulse at four times diastolic threshold, cycle lengths 200/150/100/50 ms, 10 s duration, and five repetitions). An AF episode was defined as the onset of irregular atrial electrograms with an average cycle length shorter than 150 ms for more than 10 s.

**Magnetic resonance imaging studies**

After EP studies, six DOCA and a subgroup of seven CTRL pigs underwent magnetic resonance imaging using a 3T MR system (Magnetom Trio, Siemens Healthcare, Erlangen, Germany). Cardiac function was assessed from retrospectively electrocardiogram-gated, two-dimensional segmented FLASH (fast low-angle shot) cine images obtained under free breathing, using two-fold averaging to suppress breathing artefacts. For LV function and muscle mass assessment, the LV was covered by gapless slices in short-axis orientation (measured temporal resolution 27 ms interpolated to 40 cardiac phases per cardiac cycle; echo time, 2.7 ms; flip angle, 20°; and voxel size, 1.9 × 1.6 × 8.0 mm\(^3\)), and for atrial function evaluation, LA and RA were covered by gapless slices in long-axis orientation (measured temporal resolution 45 ms interpolated to 25 cardiac phases per cardiac cycle; echo time, 2.9 ms; flip angle, 15°; and voxel size, 2.5 × 1.8 × 4.0 mm\(^3\)).

**ESC Heart Failure 2021; 8: 151–161**

DOI: 10.1002/ehf2.13087
Left ventricular function parameters [end-diastolic volume, LV end-diastolic volume; end-systolic volume, LV end-systolic volume; ejection fraction (EF), and LVEF], LV mass (including papillary muscles and trabecles to the myocardium), and atrial volumes were derived by manual segmentation (Figure 1A) using the Simpson approach (Argus, Siemens, Erlangen, Germany). LA and RA maximum, minimum, and before contraction (V_{bc}) volumes were derived from respective volume vs. time curves (Figure 2B). Pulmonary veins and mitral valve area were excluded from left, vena cava inferior/superior, coronary sinus, and tricuspid valve area from RA volumes by straight cut planes. Total EF is defined as total filling volume divided by the maximum volume, the passive EF as passive emptying volume divided by the maximum volume, and the contractile EF as active emptying volume divided by the volume before contraction (in per cent).

**Cell isolation**

All chemicals were obtained from Sigma-Aldrich, Germany, if not stated otherwise. For organ explantation, pigs were premedicated as described earlier. Endotracheal intubation was performed after intravenous administration of propofol 1% (0.1 mL/kg). Narcosis was sustained with fentanyl (35 μg/kg/h) and midazolam (1.2 mg/kg/h), and bolus of heparine (100 IE/kg) and pancuronium (0.2 mg/kg) were administered. The heart was removed via thoracotomy and kept in cardioplegic solution (in mM: NaCl 130, KCl 27, MgSO₄ 10, glucose 11).

**Figure 1** Left (LA) and right atrial (RA) remodelling and function in chronic arterial hypertension. (A) Long-axis magnetic resonance imaging images at the centre of the mitral valve (MV, left) and tricuspid valve (TV, right). Segmentation of left (solid line) and right (dashed line) atrial areas for volumetric assessment. (B) Schematic drawing of the atrial volume vs. time curve. Maximum volume, minimum volume, and volume before contraction (V_{bc}) are indicated (see Methods). Left and right maximal (C), minimal (D) volumes, and volumes before contraction (E) as well as total (F), passive (G), and contractile (H) ejection fraction (EF) from magnetic resonance imaging analysis of seven control (CTRL) and six 11-deoxycorticosterone acetate (DOCA) pigs (mean ± standard error of the mean, *P < 0.05). CS, cell shortening; LV, left ventricular; PV, pulmonary vein; RV, right ventricular; VC, vena cava.
1.2, pyruvate 2, Na L-lactate 1, glucose 12.5, and 2,3-butanedione monoxime 20). LA and RA were alternately assigned to cell isolation and to sampling of tissue for histological and protein expression studies.

For myocyte isolation, intact atria were cannulated through the left circumflex artery (LA cells) or right coronary artery (RA cells) and mounted on a Langendorff set-up. Ventricles were removed, perfusion was checked, and leaky atrial branches were ligated. The atria were perfused using a Ca²⁺-free Tyrode’s solution (in mM: NaCl 130, KCl 5.4, MgSO₄ 1.2, pyruvate 2, Na L-lactate 1, and glucose 12.5) for 10 min. Liberase (in mg/mL: CTRL 0.12 and DOCA 0.18, Roche, USA) was added, and perfusion continued for 25 min. After washout of the enzyme solution, tissue was cut into small pieces for mechanical dispersion, followed by stepwise increase of [Ca²⁺] in the external solution to 1.8 mM. Myocytes were stored at room temperature and used for experiments within 8 h.

**Cardiomyocyte Ca and contractility**

Changes in intracellular Ca and cell length were recorded simultaneously in Fura-2AM-loaded cells (1 μM) during field stimulation (0.5–2 Hz). Cell shortening was monitored with a video-based sarcomere length detection system (Myocam and SarcLen, IonOptix Corporation) at 120 Hz frame rate and expressed as fractional shortening, that is, normalized to resting sarcomere length, ΔL/L₀. Changes in Ca were expressed as Fura-2 emission ratio (F₃40/F₃80, Myocyte Calcium and Contractility System, IonOptix, on a Zeiss Axiovert 200 Microscope). For caffeine experiments, the cells were plated on laminin-coated glass coverslips to avoid moving artefacts of the cell during fast solution switches. The sarcoplasmic reticulum (SR) Ca content was qualitatively assessed by the amplitude of the caffeine-induced Ca transient (20 mM) following 1 Hz stimulation. As an indirect indication of release efficiency, we estimated fractional release by normalizing the
amplitude of the stimulated Ca²⁺ transient (CaT) to SR Ca load (ΔCaT/caffT). Ca decline in the presence of caffeine was fitted by a single exponential and is expressed as the decay time constant, τcaff. In the presence of caffeine, this parameter mainly reflects Ca removal by NCX. The decay constant of the CaT during steady-state electrical stimulation attributed to SR Ca²⁺-ATPase (SERCA) activity (τSERCA) was calculated from the decay constant of the Ca transient (τSS) and τcaff obtained from the same cell as previously described.14

Caffeine was applied before and after 8 min wash-in of 3 μM ORM-10103 to inhibit NCX.15 The drug (Orion Pharma, Espoo, Finland) was kindly provided by Dr Acsai. Experiments were performed at 37°C.

Histology and immunoblotting

For histological analysis of fibrosis, atrial tissue samples were collected and embedded in formalin and stained with Picrosirius Red to assess collagen content. Cell size was quantified as cross-sectional myocyte area in haematoxylin–eosin-stained tissue slices. Myocyte area of at least 50 cardiomyocytes per animal and region (LA/RA) were measured at ≥200 total magnification in 5 μm slices in a central plane, that is, at the level of the nucleus. Image analysis (outlining and area calculation) was performed with ImageJ (Version 1.47, National Institutes of Health). For Western blot analysis, tissue samples were snap frozen in liquid nitrogen and stored at −80°C till homogenization. Separation by sodium dodecyl sulfate–polyacrylamide gel electrophoresis and Western blot was performed according to standard immunoblotting procedures. Membranes were probed with anti-SERCA2a (1/3000, Badrilla, UK), anti-NCX (1/5000, Abanova), anti-phospho-Ser16 phospholamban (PLB) (1/17 000, Badrilla), anti-phospho-Thr17 PLB (1/25 000, Badrilla), anti-PLB (1/5000, Abcam), anti-plasmalemmal Ca pump (1/1000, Santa Cruz, USA), anti-calsequestrin (1/5000, Thermo Scientific, Germany), and anti-glyceraldehyde 3-phosphate dehydrogenase (Abcam, UK). Anti-rabbit or anti-mouse immunoglobulin G linked with horseradish peroxidase (GE Healthcare) were used as a secondary antibody. Ponceau S staining was used to normalize protein expression. Data were averaged from three replicate gels for each sample.

Statistical analysis

Average data are presented as mean ± standard error of the mean. N refers to number of animals, and n refers to number of cells. For comparisons between groups, unpaired Student’s t-test or one-way ANOVA was used. Drug effects within groups were analysed using Student’s t-test for paired measurements. For frequency-dependent effects, two-way ANOVA for repeated measurements was used with Bonferroni post hoc testing. Data analysis was performed in GraphPad Prism 6. Differences were considered significant when P < 0.05.

Results

After 12 weeks of DOCA plus high-salt/glucose diet, non-invasive systolic blood pressure was significantly higher as compared with CTRL (142 ± 37 mmHg in DOCA vs. 97 ± 6 mmHg in CTRL, P < 0.001, Table 1). DOCA pigs developed signs of LV hypertrophy evidenced by an increase in LV mass (134 ± 9 vs. 100 ± 7 g, P < 0.05). Magnetic resonance imaging (MRI) studies in a subgroup of animals revealed that LV end-diastolic volume and LV end-systolic volume remained unchanged and that LVEF was preserved (53 ± 2% in DOCA vs. 52 ± 1% in CTRL, n.s., Table 1). All pigs were in sinus rhythm (86 ± 4 b.p.m. in DOCA vs. 89 ± 2 b.p.m. in CTRL under anaesthesia).

Atrial contractility is impaired in hypertensive pigs

In vivo LA and RA function were studied by MRI (Figure 1J). LA end-diastolic (LA Vmax), end-systolic volumes (LA Vmin), and LA volumes before contraction (LA Vbc) were larger in DOCA pigs (LA Vmax 48 ± 4 vs. 37 ± 2 mL, LA Vmin 29 ± 3 vs. 16 ± 1 mL, and LA Vbc 39 ± 5 vs. 27 ± 1 mL; DOCA vs. CTRL, all P < 0.05, Figure 1C–1E). This was associated with an impaired total LAEF largely due to a reduced contractile EF in the DOCA group (LAEF 38 ± 5% vs. 55 ± 1%, LA contractile EF 23 ± 4% vs. 38 ± 3%; DOCA vs. CTRL, P < 0.05, Figure IF–1H). In RA, maximum volume and EF (total, contractile, and passive) were not significantly reduced indicating a compensatory state (Figure 1D), but there was a trend towards

| Table 1 BP and LV function in the DOCA model |
|---------------------------------------------|
| CTRL (n = 7) | DOCA (n = 5) | P   |
|----------------|-------------|-----|
| BP (mmHg) | 97 ± 6 | 142 ± 37 | 0.0003 |
| HR (b.p.m.) | 89 ± 2 | 86 ± 4 | 0.42 |
| LVEDV (mL) | 43 ± 1 | 45 ± 5 | 0.98 |
| LVEDV (mL) | 111 ± 3 | 108 ± 8 | 0.86 |
| LVEF (%) | 52 ± 1 | 53 ± 2 | 0.99 |
| LV mass (g) | 100 ± 7 | 134 ± 9 | 0.014 |
| Weight (kg) | 58 ± 3 | 66 ± 1 | 0.09 |

BP, blood pressure; CTRL, control; DOCA, 11-deoxycorticosterone acetate; HR, heart rate; LV, left ventricular; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume.

The main characteristics of DOCA animals included into the magnetic resonance imaging series. Systolic BP and LV myocardial mass were significantly higher in DOCA animals.
similar changes in total and contractile EF as in LA (Figure 1F–IH, \(P = 0.13\) and 0.14, respectively).

Along with reduced atrial contractile function, DOCA pigs showed a higher inducibility of AF episodes after burst pacing (Figure 2A–C). Atrial refractory period was not significantly different, although there was a tendency towards shortening in DOCA vs. CTRL at faster pacing cycle lengths (Figure 2C, \(P = 0.09\)). At tissue level, there were no signs of interstitial fibrosis (Figure 2D). Cardiomyocyte area was larger in LA and RA from DOCA pigs vs. CTRL, indicating cellular hypertrophy in both atria (Figure 2E).

**Atrial dysfunction is related to reduced atrial cardiomyocyte contractility**

We investigated whether loss of contractile function in the atria was related to reduced intrinsic cardiomyocyte contractile function. Isolated cardiomyocytes from LA and RA were paced at different frequencies, and cytosolic CaTs were measured (Figure 3). Atrial myocytes from healthy pigs showed a positive cell shortening-frequency response, which was related to a frequency-dependent increase in CaT amplitude. In DOCA cells, the amplitude of contraction and CaT was overall reduced and the positive frequency response was attenuated. The frequency-dependent acceleration of CaT decay and relaxation were preserved in DOCA cells, and relaxation kinetics (not shown) were not different between groups. In the LA but not RA, we observed a small but significant overall prolongation of Ca\(^{2+}\) decay in DOCA vs. CTRL, which was more pronounced at lower pacing frequencies (Figure 3A and 3B).

**Mechanisms of cardiomyocyte dysfunction differ in the right and left atria**

In a parallel set of experiments, we performed a more detailed analysis of Ca release and removal. Diastolic cytosolic [Ca\(^{2+}\)] was not changed (Figure 4A 1 and 4B 1, left). In LA cardiomyocytes, reduced CaT amplitude was related to significantly reduced SR Ca\(^{2+}\) content; fractional release as a
measure of the efficacy of Ca\(^{2+}\)-induced Ca\(^{2+}\) release was not significantly changed (Figure 4A\(_2\)). In RA, reduced CaT amplitude was related to reduced Ca\(^{2+}\)-induced Ca\(^{2+}\) release efficacy, whereas SR Ca\(^{2+}\) content was not significantly changed (Figure 4B\(_2\)).

The decline of the Ca transient during a caffeine response is mainly mediated by NCX, and thus, the decay constant ($\tau_{\text{caff}}$) is a measure of NCX forward mode activity (i.e. Ca extrusion in exchange for Na influx). In DOCA, NCX forward mode activity was not significantly altered (Figure 4A\(_2\) and 4B\(_2\)). Similarly, at the protein expression level, we did not detect differences in the abundance of NCX, SERCA, the plasmalemmal Ca pump, or PLB phosphorylation (Supporting Information, Figure S2).

**Partial sodium–calcium exchanger inhibition improves atrial contractility of the left atrium, but not in the right atrium**

In a subset of cells, we examined if partial NCX block had a positive inotropic effect on atrial contraction by increasing cellular Ca load through inhibition of forward mode NCX, thus preventing Ca removal from the cell. ORM-10103 slowed the rate of Ca decline (Figure 5A), confirming effective inhibition of NCX. Inhibition was comparable between LA and RA, CTRL and DOCA (Figure 5B), blocking 50–70% of NCX activity (Figure 5C). Indeed, inhibition of NCX induced an increase in CaT amplitude and SR Ca content in LA, but not in RA (Figure 5D and 5E). Interestingly, CaT decay was significantly accelerated by NCX inhibition in LA and RA (Figure 5F).

**Discussion**

In this study, we have investigated atrial remodelling and atrial function in a large animal model of HHD. We demonstrate that LA remodelling and LA dysfunction occur in the absence of LA fibrosis and show that LA dysfunction was related to contractile dysfunction of the hypertrophied LA cardiomyocytes. Cellular dysfunction was also observed in RA cardiomyocytes. Here, we provide evidence that the mechanisms of maladaptation differ in LA and RA cardiomyocytes and, furthermore, that dysfunctional LA and
RA cardiomyocytes respond differently to a targeted therapeutic approach with an NCX inhibitor.

Arterial hypertension is a common trigger of LV remodeling, often resulting in HHD with LV diastolic dysfunction and LA enlargement. LA enlargement is also a hallmark of HF with preserved EF. In the current model, animals did not show signs or symptoms of HF at baseline (LV end-diastolic pressure and cardiac output at rest were unchanged as previously reported). However, in an earlier study, we could show that the cardiac functional reserve was reduced during dobutamine stress. These findings may be interpreted as early signs of HF with preserved EF and emphasize the role of stress testing as recently recommended.

Left atrial dysfunction contributes to reduced exercise tolerance and is prognostically relevant. The mechanisms leading to LA dysfunction and the prevalence of RA dysfunction, however, are not well understood. In patients with (paroxysmal or persistent) AF, LA dysfunction has been associated with atrial fibrosis. Yet little is known about the prevalence of atrial fibrosis in patients with atrial dysfunction in the absence of AF. Interestingly, in the present model of HHD, LA and RA dysfunction occurred in the absence of atrial fibrosis, while in other animal models of arterial hypertension, atrial fibrosis was detected. In contrast to these models of aortic banding and renovascular hypertension, the present DOCA model mimics low-renin hypertension, which is observed in about one-third of all patients with arterial hypertension. Our observations are in line with a strong role of renin–angiotensin system activation as a trigger for atrial fibrosis. In a previous study, however, we demonstrated that DOCA-induced arterial hypertension does promote atrial fibrosis in the presence of atrial tachycardia. Thus, combining our results provides evidence that common risk factors such as arterial hypertension and atrial tachyarrhythmia—similarly promoting an arrhythmogenic substrate (see Figure 2 and Manninger et al.)—lead...
to aetiology-specific structural atrial remodelling. We cannot exclude that atrial fibrosis may contribute to atrial dysfunction in our model at later disease stages. For instance, atrial fibrosis was observed (only) with long-standing arterial hypertension in spontaneously hypertensive rats. In line with such late changes, low-voltage areas in atrial myocardium suggestive of increased fibrosis were found in patients with long-standing arterial hypertension.

While atrial myocyte function has been extensively studied in the context of atrial remodelling driven by AF, only a few studies investigated atrial myocyte function in rodent models of HHD. In ageing spontaneously hypertensive rats, alterations in Ca homeostasis occurred early in LA cardiomyocytes, even before cardiomyocyte hypertrophy but with the onset of atrial fibrosis. However, despite reduced Ca influx through L-type Ca channels and reduced RyR expression, the amplitude and kinetics of LA cardiomyocyte CaT remained compensated. Only at later stages, in the transition from ageing HHD to HF with reduced EF and overt LA enlargement, CaT amplitudes, SR Ca content, and SERCA function in LA myocytes were reduced. Reduced LA cardiomyocyte CaT amplitudes with reduced SR Ca content were also reported after aortic banding in rats. In contrast, we have shown in another model of HHD with increased LVEDP (ZSF-1 lean rats) and a preserved LAEF that the CaT amplitude in LA cardiomyocytes was increased vs. wild type, suggesting compensation of increased LA mechanical load. In HHD combined with metabolic syndrome, however, LA function in vivo deteriorated despite increased LA cardiomyocyte CaT amplitude, possibly related to increased atrial fibrosis.

The present study sheds light on cellular mechanisms of atrial dysfunction in a large animal model with heart size comparable with human. At the stage of manifest atrial remodelling in vivo, LA cardiomyocytes failed to compensate increased mechanical load but rather contributed to deterioration of LA function by a reduced contractility at baseline and reduced contractile reserve. Reduced CaT amplitude despite unaltered SERCA expression suggests a reduced availability of Ca to trigger Ca-induced Ca release. Similar changes have been observed in senescent human atrial cardiomyocytes, suggesting that age and mechanical load may synergistically contribute to atrial myocyte dysfunction.

Interestingly, in the present large animal model of HHD, RA cardiomyocyte contractile function was also significantly impaired. As outlined earlier and reviewed earlier, mechanical load is an important trigger for atrial remodelling. Increased RA volume in DOCA in vivo suggests that mechanical stress also served as a trigger for RA remodelling. Systemic neurohumoral overactivation is an additional external trigger that may have affected both RA and LA remodelling. Indeed, while DOCA treatment suppresses renin–angiotensin system activity (reduced plasma renin activity, levels of angiotensin I and II, and aldosterone), sympathetic activation as reflected by plasma norepinephrine is elevated in DOCA pigs even at low DOCA. Thus, while RA and LA have experienced similar triggers of remodelling, preserved SR Ca and increased NCX activity in RA vs. LA cardiomyocytes suggests that RA and LA cardiomyocytes responded differentially to these external stressors. These differences may in part be related to the extent and relation of mechanical, neurohumoral and possibly paracrine stress sensed by the RA vs. the LA. In addition, an intrinsic diversity in the stress response between RA and LA cardiomyocytes was recently suggested, which may contribute to our observed differences between LA and RA and warrants further study.

The sarcolemmal NCX exports Ca out of the cytosol in exchange for Na (forward mode) generating a potentially arrhythmogenic depolarizing inward current. NCX inhibitors have shown to reduce arrhythmias and also have the potential to increase cardiomyocyte inotropy by augmenting cytosolic Ca. We used the NCX inhibitor ORM-10103, a new compound with improved NCX specificity and no effects on L-type Ca influx. Partial NCX inhibition might be an interesting strategy to improve atrial contractility in salt-sensitive hypertension because of its documented blood pressure lowering effects in this condition. Indeed, we found that ORM-10103 increases CaT amplitude and SR Ca in LA cardiomyocytes from DOCA (Figure 5D). This was not associated with a slowed but rather an accelerated Ca removal from the cytosol, which may be explained by reduced competition for SERCA-mediated Ca removal or the inhibition of additional reverse mode activity of the NCX at different phases of the cardiac cycle as described earlier. The response of RA cardiomyocytes to NCX inhibition (Figure 5D–5F) suggested that in RA vs. LA cardiomyocytes, NCX activity may be shifted more to reverse mode (Ca import) during the cardiac cycle.

**Limitations**

In the present model, non-invasive blood pressure was measured only at the end of the observation period to minimize the number of anaesthesia per animal (3R). However, DOCA sustained release pellets are a well-established intervention to induce elevated blood pressure, and we have previously reported a robust and reproducible increase in arterial blood pressure in this model. DOCA pigs tended to have a higher body weight than CTRL at the time of final experiment (Table 1). However, similar systolic and diastolic LV volumes in both groups suggest that the observed trend in body weight had little impact on cardiac cavity size. Our measurements in isolated cardiomyocytes point at impaired Ca homeostasis with intrinsic atrial myocyte dysfunction as the cellular substrate for atrial cardiomyopathy in this model; however, upstream intracellular and potential extracellular signalling needs to be further

---

*ESC Heart Failure 2021; 8: 151–161
DOI: 10.1002/ehf2.13087*
explored. While we have investigated the potential benefit of NCX inhibition to increase SR Ca and improve CaT amplitudes in diseased animals as a proof of concept, we did not extend this approach to healthy animals. We believe our results provide proof of concept for an effect in diseased animals and evidence for a subsequential in-depth pharmacodynamic safety evaluation of NCX inhibition on atrial function in vitro and in vivo.

In summary, in this large animal model of HHD, atrial remodelling and contractile dysfunction occur in the absence of atrial fibrosis. Cardiomyocyte contractile dysfunction with reduced inotropy is present in LA and also in RA in the absence of HF. Improving atrial cardiomyocyte inotropy should be evaluated as a therapeutic aim in HHD.

Conflict of interest

None declared.

References

1. Hohendanner F, Messroghli D, Bode D, Blaschke F, Parwani A, Boldt LH, Heinzel FR. Atrial remodelling in heart failure: recent developments and relevance for heart failure with preserved ejection fraction. ESC Heart Fail 2018; 5: 211–221.

2. Santos AB, Roca GQ, Claggett B, Sweitzer NK, Shah SJ, Anand IS, Fang JC, Zile MR, Pitt B, Solomon SD, Shah AM. Prognostic relevance of left atrial dysfunction in heart failure with preserved ejection fraction. Circ Heart Fail 2016; 9: e002763.

3. von Roeder M, Rommel KP, Kowallick JT, Blazek S, Besler C, Fengler K, Lotz J, Hasenfuß G, Lücke C, Guterlet M, Schulzer G. Influence of left atrial function on exercise capacity and left ventricular function in patients with heart failure and preserved ejection fraction. Circ Cardiovasc Imaging 2017; 10: e005467.

4. D’Andrea A, Caso P, Romano S, Scarafile R, Cuomo S, Salerno G, Rieglar L, Limongelli G, Di Salvo G, Romano M, Liccardo B. Association between left atrial myocardial function and exercise capacity in patients with either idiopathic or ischemic dilated cardiomyopathy: a two-dimensional speckle strain study. Int J Cardiol 2009; 132: 354–363.

5. Cuspidi C, Rescaldani M, Sala C. Prevalence of echocardiographic left-atrial enlargement in hypertension: a systematic review of recent clinical studies. Am J Hypertens 2013; 26: 456–464.

6. Tadic M, Cuspidi C, Suzic-Lazic J, Andric A, Stojcevski B, Ivanovic B, Hot S, Scepanovic R, Celic V. Is there a relationship between right-ventricular and right atrial mechanics and functional capacity in hypertensive patients? J Hypertens 2014; 32: 929–937.

7. Goette A, Kalman JM, Aguinaga L, Akar C, Cabrera JA, Chen SA, Chugh SS, Corradi D, D’Avila A, Dobrev D, Fenelon G. EHRA/HRSA/APHRS/SOLACE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication. Europace 2016; 18: 1455–1490.

8. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibration begets atrial fibrillation: a study in awake chronically instrumented goats. Circulation 1995; 92: 1954–1968.

9. Männiger M, Zweiker D, van Hunnik A, Alogna A, Prassl AJ, Schipke J, Zeeemerling S, Zimzgast B, Schönleitner P, Schwarzl M, Herbst V. Arterial hyper-tension drives arrhythmia progression via specific structural remodeling in a porcine model of atrial fibrillation. Heart Rhythm 2018; 15: 1328–1336.

10. Lau DH, Shipp NJ, Kelly DJ, Thanigaimani S, Neo M, Kuklik P, Lim HS, Zhang Y, Drury K, Wong CX, Chia NH. Atrial arrhythmia in ageing spontaneously hypertensive rats: unraveling the substrate in hypertension and ageing. PLoS ONE 2013; 8: e72416.

11. Lau DH, Mackenzie I, Kelly DJ, Psaltis PJ, Brooks AG, Worthington M, Rajendram A, Kelly DR, Zhang Y, Kuklik P, Nelson AJ. Hypertension and atrial fibrillation: evidence of progressive atrial remodeling with electrostructural correlate in a conscious chronically instrumented ovine model. Heart Rhythm 2010; 7: 1282–1290.

12. Pluteanu F, Nikonova Y, Holzapfel A, Herzog B, Scherer A, Preisenerberger J, Plačkic J, Scheer K, Ivanova T, Bukowska A, Goette A. Progressive impairment of atrial myocyte function during left ventricular hypertrophy and heart failure. J Mol Cell Cardiol 2018; 114: 253–263.

13. Pluteanu F, Hess J, Plačkic J, Nikonova Y, Preisenerberger J, Bukowska A, Schotten U, Rînne A, Kienitz MC, Schäfer MK, Weihe E. Early subcellular Ca2+ remodelling and increased propensity for Ca2+ alternans in left atrial myocytes from hypertensive rats. Cardiovasc Res 2015; 106: 87–97.

14. Iwamoto T, Kita S, Zhang J, Blaustein JT, Hasenfuß G, Lücke C, Gutberlet M, Meyer MP, Arai Y, Yoshida S, Wakimoto K, Komuro I, Katsuragi T. Salt-sensitive hypertension is triggered by Ca2+ entry via Na+/Ca2+ exchanger type-1 in vascular

Funding

This work was supported by the European Commission (Grant No. 261057; European Network for Translational Research in Atrial Fibrillation (EUTRAF), Grant No. 633196. M.M. and G.J. received funding from the Medical University of Graz (Medizinische Universität Graz) within the PhD Program Molecular Medicine. G.J. was supported by the funds of Wenzhou Municipal Science and Technology Bureau (Grant No. Y20160029).

Supporting information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Figure S1. Animal usage.

Figure S2. Protein expression of NCX, SERCA and PMCA, phosphorylation of phospholamban as determined by Western blot. See text for details.
smooth muscle. Nat Med 2004; 10: 1193–1199.

15. Nagy N, Kormos A, Kohajda Z, Szebeni A, Szepesi J, Pollesello P, Levjoki J, Acsai K, Virág L, Nánási PP, Papp JG. Selective Na+/Ca2+ exchanger inhibition prevents Ca2+ overload-induced triggered arrhythmias. Br J Pharmacol 2014; 171: 5665–5681.

16. Schwarzl M, Hamdani N, Seiler S, Alogna A, Manninger M, Reilly S, Zirngast B, Kirsch A, Steendijk P, Verderber J, Zweiker D. A porcine model of hypertensive cardiomyopathy: implications for heart failure with preserved ejection fraction. Am J Physiol Heart Circ Physiol 2015; 309: H1407–H1418.

17. Reiter U, Reiter G, Manninger M, Adelsmayr G, Schipke J, Alogna A, Rajces A, Stalder AF, Greiser A, Mühlfeld C, Scherr D. Early-stage heart failure with preserved ejection fraction in the pig: a cardiovascular magnetic resonance study. J Cardiovasc Magn Reson 2016; 18: 63.

18. Pieske B, Tshopec O, de Boer RA, Fraser AG, Anker SD, Donal E, Edelmann F, Fu M, Guazzi M, Lam CS, Lancellotti P. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail 2020; 22: 391–412.

19. Habibi M, Lima JA, Khurrum IM, Zimmermann SI, Zipunnikov V, Fukumoto K, Spragg D, Ashikaga H, Rickett J, Marine JE, Calkins H. Association of left atrial function and left atrial enhancement in patients with atrial fibrillation: cardiac magnetic resonance study. Circ Cardiovasc Imaging 2015; 8: e002769.

20. Lau DH, Mackenzie L, Rajendram A, Psaltis PJ, Kelly DR, Spyropoulos P, Zhang Y, Olakengil SA, Russell CH, Brooks AG, Faull RJ. Characterization of cardiac remodeling in a large animal “one-kidney, one-clip” hypertensive model. Blood Press 2010; 19: 119–125.

21. Wei W, Rao F, Liu F, Xue Y, Deng C, Wang Z, Zhu J, Yang H, Li X, Zhang M, Fu Y. Involvement of Smad3 pathway in atrial fibrosis induced by elevated hydrostatic pressure. J Cell Physiol 2018; 233: 4981–4989.

22. Kim SJ, Choisy SC, Barman P, Zhang H, Hancock JC, Jones SA, James AF. Atrial remodeling and the substrate for atrial fibrillation in rat hearts with elevated afterload. Circ Arrhythm Electrophysiol 2011; 4: 761–769.

23. Monticone S, Burrello J, Tizzani D, Bertello C, Viola A, Buffolo F, Gabetti L, Mengozzi G, Williams TA, Rabbia F, Veglio F. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol 2017; 69: 1811–1820.

24. Medi C, Kalman JM, Spence SJ, Teh AW, Lee G, Bader I, Kaye DM, Kistler PM. Atrial electrical and structural changes associated with longstanding hypertension in humans: implications for the substrate for atrial fibrillation. J Cardiovasc Electrophysiol 2011; 22: 1317–1324.

25. Zhang H, Cannell MB, Kim SJ, Watson JJ, Norman R, Calaghan SC, Orchard CH, James AF. Cellular hypertrophy and increased susceptibility to spontaneous calcium-release of rat left atrial myocytes due to elevated afterload. PLoS ONE 2015; 10: e0144309.

26. Hohendanner F, Bode D, Primessnig U, Guthof T, Doerr R, Jeuthe S, Reimers S, Zhang K, Bach D, Wakula P, Pieske BM. Cellular mechanisms of metabolic syndrome-related atrial decompensation in a rat model of HFpEF. J Mol Cell Cardiol 2018; 115: 10–19.

27. Herrera-Martinez A, Alvarez-Garcia J, Llach A, Molina CE, Fernandes J, Ferrero-Gregori A, Rodriguez C, Valmitjana A, Benitez R, Padro JM, Martinez-González J. Ageing is associated with deterioration of calcium homeostasis in isolated right atrial myocytes. Cardiovasc Res 2015; 106: 76–86.

28. Han W, Fang W, Gan Q, Guan S, Li Y, Wang M, Gong K, Xu Q. Low-dose sustained-release deoxycorticosterone acetate-induced hypertension in Bama miniature pigs for renal sympathetic nerve denervation. J Am Soc Hypertens 2017; 11: 314–320.

29. Le QA, Kim JC, Kim KH, Van Vu AT, Woo SH. Distinct shear-induced Ca2+ signaling in the left and right atrial myocytes: role of P2 receptor context. J Mol Cell Cardiol 2020; 143: 38–50.

30. Antoons G, Willems R, Sipido KR. Alternative strategies in arrhythmia therapy: evaluation of Na/Ca exchange as an anti-arrhythmic target. Pharmocol Ther 2012; 134: 26–42.

31. Jost N, Nagy N, Corici C, Kohajda Z, Horvath A, Acsai K, Bliczki P, Levjoki J, Pollesello P, Koskelainen T, Otsomaa L. ORM-10103, a novel specific inhibitor of the Na+/Ca2+ exchanger, decreases early and delayed afterdepolarizations in the canine heart. Br J Pharmacol 2013; 170: 768–778.

32. Primessnig U, Schonleitner P, Hull A, Pfeiffer S, Bracic T, Rau T, Kap M, Stojakovic T, Glasnov T, Leinemeyer K, Wakuula P. Novel pathomechanisms of cardiomyocyte dysfunction in a model of heart failure with preserved ejection fraction. Eur J Heart Fail 2016; 18: 987–997.

33. Alogna A, Schwarzl M, Manninger M, Hamdani N, Zirngast B, Kloth B, Steendijk P, Verderber J, Zweiker D, Westermann D, Blankenberg S. Acute stimulation of the soluble guanylate cyclase does not impact on left ventricular capacitance in normal and hypertrophied porcine hearts in vivo. Am J Physiol Heart Circ Physiol 2018; 315: H669–H680.